Decomoton

Decomoton Uses, Dosage, Side Effects, Food Interaction and all others data.

Decomoton is a long-acting synthetic octapeptide analogue of oxytocin. It acts as an agonist at peripheral oxytocin receptors, particularly in the myometrium of uterus.

Decomoton is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is sold under the trade name Duratocin. It is an analogue of oxytocin, and its action is similar to that of oxytocin; it causes contraction of the uterus.

Decomoton
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Decomoton
Generic	Carbetocin
Carbetocin Other Names	Carbetocin, Carbetocina, Carbetocino, Carbetocinum
Type
Formula	C₄₅H₆₉N₁₁O₁₂S
Weight	Average: 988.161 Monoisotopic: 987.484787417
Groups	Approved, Investigational
Therapeutic Class	Drugs acting on the Uterus
Manufacturer
Available Country	Poland
Last Updated:	September 19, 2023 at 7:00 am

Uses

Decomoton is used for the prevention of uterine atony and postpartum haemorrhage (excessive bleeding) following delivery of the infant by elective caesarean section under epidural or spinal anaesthesia.

Decomoton is also used to associated treatment for these conditions: Postpartum Haemorrhage (PPH), Uterine Atony

How Decomoton works

Decomoton binds to oxytocin receptors present on the smooth musculature of the uterus, resulting in rhythmic contractions of the uterus, increased frequency of existing contractions, and increased uterine tone. The oxytocin receptor content of the uterus is very low in the non-pregnant state, and increases during pregnancy, reaching a peak at the time of delivery.

Dosage

Decomoton dosage

A single intravenous dose of 100 mcg (1 ml) of Carbate (carbetocin injection) is administered by bolus injection, slowly over 1 minute, only when infant delivery has been completed by caesarean section under epidural or spinal anaesthesia.Carbate is to be used as a single dose only.

Side Effects

10-40% of patients experienced nausea, vomiting, abdominal pain, itching skin, increased body temperature, trembling and weakness. Infrequent adverse events (1-5% of patients) included back pain, dizziness, metallic taste, anaemia, sweating, chest pain, dyspnoea, chills, tachycardia and anxiety.

Precaution

In patients who may not have an adequate uterine contraction after a single injection of carbetocin, more aggressive treatment with additional doses of oxytocin or ergometrine is warranted.As carbetocin is closely related in structure to oxytocin, hyponatraemia may occur.Decomoton should be used cautiously in the presence of epilepsy, migraine, asthma or any state in which a rapid addition to extracellular water may produce hazard for an already overburdened system.Patients with eclampsia and pre-eclampsia should be monitored for changes in blood pressure.Decomoton is not recommended for use in elderly patients.

Interaction

No specific drug interactions have been reported with carbetocin.

Food Interaction

No interactions found.

Elimination Route

Bioavailability is 80% following intramuscular injection.

Half Life

40 minutes

Pregnancy & Breastfeeding use

Use of carbetocin injection is contraindicated during pregnancy.Use in lactationSmall amounts of carbetocin has been shown to cross over from plasma into the breast milk of nursing women. The small amount of carbetocin ingested by infant would not be expected to present a significant safety concern.

Contraindication

Do not administer before delivery. Vascular disease esp coronary artery disease; hepatic or renal disease.

Special Warning

Pediatrics:No information is available on the relationship of age to the effects of carbetocin in pediatric patients. Safety and efficacy have not been established.

Acute Overdose

Overdosage of carbetocin can be expected to produce enhanced pharmacological effects associated with uterine hyperactivity and pain. Treatment consists of symptomatic and supportive management.